Close

Saneca Pharma renews Pharmascience agreement following successful quality audit

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Oncology start-ups urged to apply and accelerate their business with Discovery Spark

Applications open for Discovery Park’s oncology themed ‘Discovery...

2025 AI Trends & Pharma Predictions

As we navigate what the future of healthcare will...

Swiss Airtainer reaches major milestone with successful completion of first 50 commercial shipments

Swiss Airtainer is pleased to announce the successful completion of its first 50 commercial shipments of high-value life science...

Contract development and manufacturing organisation (CDMO) Saneca Pharma has renewed an agreement with Pharmascience Inc, one of Canada’s largest pharmaceutical companies, for the manufacture and supply of prescription medicines in tablet form.

The agreement, which follows a successful GMP audit held in January 2018, includes the manufacture of 600 million enteric, chewable and film-coated tablets (RX medicines) per year. It will also involve R&D and laboratory analyses related to existing and emerging formulations, as well as technical support in delivery to the Canadian market.

Markus Saal, sales director at Saneca Pharma said: “Pharmascience is a big name in the pharmaceutical industry, so it’s great to work with them on a project of this size.

“Saneca Pharma produces large number of tablets for customers every year and has a huge amount of expertise, especially in solid dose manufacturing. By delivering both development and manufacturing services, we’re also able to simplify the tech transfer process to commercial production and streamline our customers’ projects, saving time and costs.

“We’re confident we’ll be able to add value to this project by combining our in-depth knowledge and our wide range of capabilities.”

The substantial agreement consists of nine different stock keeping units (SKUs), covering a number of therapeutic areas.

Pierre Plante, sourcing director at Pharmascience said: “Saneca Pharma is well located in Europe and its experience in manufacturing solid dose products was a huge part of the reason we selected them as our outsourcing partner for this project.

“Its comprehensive tech-transfer offering was also interesting for us. We look forward to continuing to develop our partnership with Saneca as we move into 2018.”

About Pharmascience
Pharmascience is one of the top ten pharmaceutical companies in Canada. The company manufactures and markets prescription, over-the-counter and behind-the-counter medicines and is responsible for filling over 45 million prescriptions each year in Canada alone. Based in Montreal, the company distributes its products across 60 countries worldwide. For more information visit www.pharmascience.com.

About Saneca Pharma
Based in western Slovakia, in close proximity to Vienna, Saneca Pharma offers its customers strong development and manufacturing capabilities for solids, semi-solids and liquids, as well as specialist expertise in tech-transfer, opiate APIs and finished dosage forms from farm to pharmacy. For more information visit www.saneca.com.

 

Latest stories